Suppr超能文献

心肌骨桥蛋白的表达与心力衰竭的发展相一致。

Myocardial osteopontin expression coincides with the development of heart failure.

作者信息

Singh K, Sirokman G, Communal C, Robinson K G, Conrad C H, Brooks W W, Bing O H, Colucci W S

机构信息

Myocardial Biology Unit and Cardiovascular Division, Department of Medicine, Boston Medical Center, Boston Veterans Affairs Medical Center, Boston University School of Medicine, Boston, MA, USA.

出版信息

Hypertension. 1999 Feb;33(2):663-70. doi: 10.1161/01.hyp.33.2.663.

Abstract

To identify genes that are differentially expressed during the transition from compensated hypertrophy to failure, myocardial mRNA from spontaneously hypertensive rats (SHR) with heart failure (SHR-F) was compared with that from age-matched SHR with compensated hypertrophy (SHR-NF) and normotensive Wistar-Kyoto rats (WKY) by differential display reverse transcriptase-polymerase chain reaction. Characterization of a transcript differentially expressed in SHR-F yielded a cDNA with homology to the extracellular matrix protein osteopontin. Northern analysis showed low levels of osteopontin mRNA in left ventricular myocardium from WKY and SHR-NF but a markedly increased (approximately 10-fold) level in SHR-F. In myocardium from WKY and SHR-NF, in situ hybridization showed only scant osteopontin mRNA, primarily in arteriolar cells. In SHR-F, in situ hybridization revealed abundant expression of osteopontin mRNA, primarily in nonmyocytes in the interstitial and perivascular space. Similar findings for osteopontin protein were observed in the midwall region of myocardium from the SHR-F group. Consistent with the findings in SHR, osteopontin mRNA was minimally increased (approximately 1.9-fold) in left ventricular myocardium from nonfailing aortic-banded rats with pressure-overload hypertrophy but was markedly increased (approximately 8-fold) in banded rats with failure. Treatment with captopril starting before or after the onset of failure in the SHR reduced the increase in left ventricular osteopontin mRNA levels. Thus, osteopontin expression is markedly increased in the heart coincident with the development of heart failure. The source of osteopontin in SHR-F is primarily nonmyocytes, and its induction is inhibited by an angiotensin-converting enzyme inhibitor, suggesting a role for angiotensin II. Given the known biological activities of osteopontin, including cell adhesion and regulation of inducible nitric oxide synthase gene expression, these data suggest that it could play a role in the pathophysiology of heart failure.

摘要

为了鉴定在从代偿性肥大转变为心力衰竭过程中差异表达的基因,通过差异显示逆转录酶 - 聚合酶链反应,将心力衰竭自发性高血压大鼠(SHR - F)的心肌mRNA与年龄匹配的代偿性肥大SHR(SHR - NF)和正常血压的Wistar - Kyoto大鼠(WKY)的心肌mRNA进行比较。对SHR - F中差异表达的一种转录本进行表征,得到了一种与细胞外基质蛋白骨桥蛋白具有同源性的cDNA。Northern分析显示,WKY和SHR - NF的左心室心肌中骨桥蛋白mRNA水平较低,但SHR - F中显著升高(约10倍)。在WKY和SHR - NF的心肌中,原位杂交显示仅在小动脉细胞中有少量骨桥蛋白mRNA。在SHR - F中,原位杂交显示骨桥蛋白mRNA大量表达,主要在间质和血管周围空间的非心肌细胞中。在SHR - F组心肌的中层区域观察到骨桥蛋白蛋白的类似结果。与SHR中的发现一致,在压力超负荷肥大的非衰竭主动脉缩窄大鼠的左心室心肌中,骨桥蛋白mRNA仅轻微增加(约1.9倍),但在衰竭的缩窄大鼠中显著增加(约8倍)。在SHR中,在心力衰竭发作之前或之后开始用卡托普利治疗可降低左心室骨桥蛋白mRNA水平的升高。因此,骨桥蛋白表达在心力衰竭发展过程中在心脏中显著增加。SHR - F中骨桥蛋白的来源主要是非心肌细胞,其诱导受到血管紧张素转换酶抑制剂的抑制,提示血管紧张素II起作用。鉴于骨桥蛋白已知的生物学活性,包括细胞粘附和诱导型一氧化氮合酶基因表达的调节,这些数据表明它可能在心力衰竭的病理生理学中起作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验